Protagonist Therapeutics (PTGX) Net Equity Issued and Repurchased (2016 - 2023)

Protagonist Therapeutics has reported Net Equity Issued and Repurchased for 8 years, with the latest figure at $8000.0 in Q4 2023.

• Quarterly Net Equity Issued and Repurchased fell 82.98% year-over-year to $8000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $24.3 million (down 77.39% YoY) and the FY2023 annual result came in at $107.8 million, up 638.34% from the prior year.
• Net Equity Issued and Repurchased grew to $8000.0 in Q4 2023 per PTGX's latest filing, from -$78000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $107.6 million in Q4 2020 and troughed at -$19.9 million in Q4 2019.
• A 5-year average of $14.1 million and a median of $3.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2019 and 2020: Net Equity Issued and Repurchased slumped 4289.47% in 2019, then soared 640.7% in 2020.
• Over 5 years, Net Equity Issued and Repurchased stood at -$19.9 million in 2019, then jumped by 640.7% to $107.6 million in 2020, then tumbled by 100.15% to -$166000.0 in 2021, then surged by 128.31% to $47000.0 in 2022, then sank by 82.98% to $8000.0 in 2023.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $8000.0, -$78000.0, and $68000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.